ILC Therapeutics’ initial drug asset is hybrid interferon Alfacyte™, which has broad-spectrum antiviral activities, activating a number of antiviral ISGs (interferon-stimulated genes).
Alfacyte™ has been in development for the past five years and has now progressed to proof of concept (PoC) in vivo assessment.
Completion of this stage will allow ILCT to progress to clinical readiness.
Drug asset life cycle
For each therapeutic application, ILC Therapeutics will progress through a well-established “drug discovery life cycle” as outlined on the left.
As an asset moves successfully along this life cycle, its value increases in a series of value inflection points.
Looking to invest?
Click below to find out more about investment opportunities.
